leadf
logo-loader
viewEmyria Ltd

Emyria medical director demonstrates faith in biotechnology strategy with on-market purchase

The company has partnered with Mt Sinai Hospital’s Precision Recovery team in New York to support ongoing development of Emyria’s Openly clinical service for the remote monitoring of patients and care coordination.

Emyria Ltd -
Emyria aims to facilitate access to new treatments and medical technologies supported by a world-class model of care.

Emyria Ltd (ASX:EMD) medical director Alistair Vickery has demonstrated his faith in the company’s biotechnology strategy with the purchase of shares in an on-market transaction.

Vickery acquired 128,000 shares on October 19, and this was his first purchase of fully paid ordinary shares in the company, formerly known as Emerald Clinics.

Partnering with New York’s Mt Sinai Hospital

In September, the company entered a professional services agreement with the Precision Recovery team at New York’s Mt Sinai Hospital, one of the USA's leading teaching and research hospitals, to support ongoing development of Emerald’s Openly clinical service.

The Precision Recovery Team is currently managing over 1,600 COVID-positive, COVID-suspected and COVID-recovering individuals remotely and has special expertise in this area.

Under the agreement, Mt Sinai’s Precision Recovery team will provide remote monitoring and consulting services to support the development and delivery of Emerald’s Openly clinical service worldwide, in exchange for access to the Openly app and a payment for any alert reviewed by the Mt Sinai team on request.

Quick facts: Emyria Ltd

Price: 0.077 AUD

ASX:EMD
Market: ASX
Market Cap: $16.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emyria Ltd named herein, including the promotion by the Company of Emyria Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

2 weeks, 5 days ago

2 min read